KERNEL HOLDING S.A. financials
KERNEL HOLDING S.A.
Country: LU Reporting currency: USD Latest annual report: 2024-06-30
LEI:
5493003GR6L4DZOS2U12 Financial statements
(USD, as reported — unscaled; 108 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | $3.58B | $3.46B |
| Cost of sales | $2.89B | $2.70B |
| Gross profit | $682.1M | $636.4M |
| Other income | $71.1M | $53.5M |
| Operating profit (EBIT) | $276.4M | $439.5M |
| Finance costs | $119.1M | $153.2M |
| Profit before tax | $211.1M | $367.8M |
| Income tax expense | $43.4M | $69.0M |
| Profit for the year | $167.6M | $298.8M |
| — attributable to owners | $168.0M | $299.2M |
| — attributable to NCI | -$324.0K | -$418.0K |
| Total comprehensive income | $62.3M | $57.8M |
| Per share | ||
| Basic EPS | $0.65 | $3.86 |
| Diluted EPS | $0.65 | $3.86 |
| Free cash flow / share | $1.28 | $8.25 |
| Cash flow statement | ||
| Cash generated from operations | $582.7M | $880.4M |
| Net cash from operating activities | $472.1M | $716.1M |
| Income taxes paid | $32.4M | $44.0M |
| Net cash from investing activities | -$112.5M | $9.6M |
| Purchase of PP&E (capex) | $142.6M | $77.1M |
| Net cash from financing activities | -$505.5M | -$215.8M |
| Proceeds from borrowings | $245.0M | $54.9M |
| Repayments of borrowings | $790.5M | $247.7M |
| Lease liability payments | $20.0M | $23.2M |
| Balance sheet | ||
| Total assets | $3.40B | $3.89B |
| Non-current assets | $1.24B | $1.44B |
| Property, plant & equipment | $944.1M | $1.02B |
| Right-of-use assets | $172.9M | $205.6M |
| Intangible assets & goodwill | $13.2M | $71.6M |
| Current assets | $2.16B | $2.44B |
| Inventories | $277.7M | $341.5M |
| Trade & other receivables | $305.2M | $321.6M |
| Cash & equivalents | $809.6M | $954.1M |
| Total equity | $1.87B | $1.74B |
| — attributable to owners | $1.86B | $1.74B |
| Non-controlling interests | $1.7M | $2.1M |
| Non-current liabilities | $163.6M | $242.4M |
| Lease liabilities (non-current) | $142.5M | $166.7M |
| Current liabilities | $1.37B | $1.90B |
| Short-term borrowings | $315.2M | $869.9M |
| Lease liabilities (current) | $27.2M | $31.2M |
| Deferred tax liabilities | $20.0M | $20.6M |
| Derived metrics | ||
| Free cash flow | $329.6M | $639.0M |
| Operating margin | 7.7% | 12.7% |
| Net margin | 4.7% | 8.6% |
| Return on equity | 9.0% | 17.1% |
| Cash conversion ratio | 2.82× | 2.40× |
| Capex coverage | 3.31× | 9.29× |
| Other reported items | ||
| Additional Paidin Capital | $39.9M | $39.9M |
| Adjusted Weighted Average Shares | 256.8M | 77.4M |
| Adjustments For Decrease Increase In Biological Assets | -$17.2M | $73.7M |
| Adjustments For Decrease Increase In Inventories | -$16.9M | $508.2M |
| Adjustments For Decrease Increase In Trade Account Receivable | $10.4M | -$177.4M |
| Adjustments For Depreciation and Amortisation Expense | $104.7M | $104.8M |
| Adjustments For Fair Value Gains Losses | -$16.5M | $29.7M |
| Adjustments For Finance Costs | $119.1M | $153.2M |
| Adjustments For Finance Income | $49.8M | $30.8M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -$530.0K | $621.0K |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | -$10.4M | -$114.7M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | $2.8M | $65.7M |
| Adjustments For Increase Decrease In Trade Account Payable | -$45.3M | $1.1M |
| Adjustments For Provisions | $14.0M | -$1.1M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$32.7M | -$61.2M |
| Cancellation of Treasury Shares | $0 | — |
| Cash and Cash Equivalents If Different From Statement of Financial Position | $809.6M | $954.1M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $92.5M | $89.7M |
| Cash Flows From Used In Operations Before Changes In Working Capital | $604.0M | $752.8M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $24.7M | $12.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | -$487.0K | -$895.0K |
| Comprehensive Income Attributable To Owners of Parent | $62.8M | $58.7M |
| Current Advances To Suppliers | $120.9M | $135.0M |
| Current Biological Assets | $187.7M | $147.9M |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | $597.6M | $596.2M |
| Current Receivables From Taxes Other Than Income Tax | $114.1M | $162.3M |
| Current Tax Assets Current | $227.0K | $3.6M |
| Current Tax Liabilities Current | $31.4M | $12.9M |
| Deferred Tax Assets | $35.6M | $21.4M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $1.4M | -$3.4M |
| Equity and Liabilities | $3.40B | $3.89B |
| Finance Income | $49.8M | $30.8M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | $33.0M | $62.6M |
| Gains Losses On Fair Value Adjustment Biological Assets | -$10.4M | -$114.7M |
| Income Tax Relating To Changes In Revaluation Surplus of Other Comprehensive Income | -$1.8M | $0 |
| Increase Decrease In Cash and Cash Equivalents | -$144.5M | $506.5M |
| Intangible Assets Other Than Goodwill | $36.4M | $36.3M |
| Interest Paid Classified As Operating Activities | $110.9M | $148.4M |
| Interest Received Classified As Operating Activities | $32.8M | $28.1M |
| Issue of Equity | $60.0M | — |
| Issued Capital | $7.7M | $2.2M |
| Noncurrent Financial Assets | $23.3M | $25.5M |
| Other Comprehensive Income | -$105.3M | -$241.0M |
| Other Comprehensive Income Before Tax Gains Losses On Revaluation | -$9.9M | $0 |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -$97.2M | -$241.0M |
| Other Current Financial Assets | $339.9M | $376.1M |
| Other Current Financial Liabilities | $101.2M | $68.6M |
| Other Expense By Function | $22.9M | $34.9M |
| Other Gains Losses | -$29.1M | -$11.8M |
| Other Noncurrent Assets | $16.0M | $62.2M |
| Other Noncurrent Liabilities | $986.0K | $55.1M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | $10.2M | $2.7M |
| Reserve of Exchange Differences On Translation | -$1.03B | -$932.1M |
| Retained Earnings | $2.29B | $2.12B |
| Revaluation Surplus | $96.2M | $104.3M |
| Selling General and Administrative Expense | $213.4M | $205.0M |
| Share Premium | $457.9M | $500.4M |
| Trade and Other Current Payables To Trade Suppliers | $109.7M | $158.6M |
| Treasury Shares | $0 | $96.9M |
| Weighted Average Shares | 256.8M | 77.4M |
Methodology
Every line item above is a fact tagged in KERNEL HOLDING S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.